Poland – Medicinal products for the blood and blood-forming organs – SUBSTANCJA CZYNNA EMICIZUMAB wraz z sukcesywnymi dostawami do Centrów Leczenia Hemofilii; znak postępowania: ZZP.ZP.411.84.2026
Opportunity Score
Confidence: 60%
Complexity: medium
18 days
Deadline
supplies
Contract
Deep Portfolio Analysis
- Company fit score
- Missing certificates
- Eligibility blockers
- Bid / No-Bid recommendation
AI Analysis Summary
Tender for successive deliveries (2026-2028) of the active substance Emicizumab (for hemophilia A) with administration sets, home delivery to patients, waste management, and patient education under the Polish NFZ drug program. Single lot, electronic submission, Polish language.
Strengths
Documents available
Open procedure
Medium complexity
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
- Product must have a valid refund decision by 1 May 2026
- Total quantity: 961,368 mg (basic purchase for 2026-2028)
- Valid marketing authorization for the medicinal product in Poland or EU
Buyer
Name
Instytut Matki i Dziecka
Location
Warszawa, POL
Website
Buyer profile
Identifier
5250008471
Lots (1)
Supply of Emicizumab (961,368 mg total), administration sets, home delivery, waste containers/collection, drug consumption monitoring, and education. Deliveries to Hemophilia Treatment Centers and patient homes in Poland.
Procurement Details
Publication
02 Jun 2026
Deadline
03 Jul 2026, 09:00
Procedure
open
Contract
supplies
Language
POL
Publication #
379135-2026
Classification
Performance: Poland
Documents (2)
Opportunity Score
Confidence: 60%
Complexity: medium
18 days
Deadline
supplies
Contract
Deep Portfolio Analysis
- Company fit score
- Missing certificates
- Eligibility blockers
- Bid / No-Bid recommendation